---
layout: default
title: Alpha -Tocopherol Acetate Dl- Ascorbic Acid Cyanoc
parent: 僅模型預測 (L5)
nav_order: 236
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate Dl- Ascorbic Acid Cyanoc
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multivitamin + Fluoride Combination: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This candidate is a multi-component vitamin and mineral supplement containing eleven active ingredients (Vitamins A, B1, B2, B3, B6, B9, B12, C, D, E, and Sodium Fluoride), commonly used as a nutritional supplement or preventive micronutrient formula. The TxGNN model returned **no predicted new indications** for this combination, and no supporting clinical trials or literature were identified. As a result, a repurposing evaluation cannot be conducted at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not registered in US; indication unknown |
| Predicted New Indication | None (no TxGNN output) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no output) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this drug combination, so a mechanism-based rationale for repurposing cannot be presented.

From a pharmacological standpoint, this is a fixed-dose multivitamin and fluoride combination. The individual components (fat-soluble vitamins A, D, E; water-soluble B-complex vitamins; ascorbic acid; and sodium fluoride) collectively support basic metabolic functions, immune homeostasis, neurological integrity, bone mineralisation, and antioxidant defence. Such combinations are typically positioned as nutritional supplements rather than disease-modifying agents, which may explain the absence of TxGNN output — the model is optimised for disease–drug interactions rather than nutritional adequacy endpoints.

Additionally, the absence of a DrugBank ID for this specific combination limits automated mechanism retrieval. Individual components do have well-characterised DrugBank entries, but the composite formulation is not recognised as a single entity in the knowledge graph.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This drug combination has no recorded NDA licenses in the Evidence Pack. The US market status is listed as **Not marketed (未上市)** with zero authorisations on record.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** All safety fields (key warnings, contraindications, drug–drug interactions) returned no data in the current Evidence Pack. Given that this is a multi-component formulation, individual component safety profiles should be reviewed separately through DrugBank and the relevant prescribing information before any clinical decision is made.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline produced no predicted indications for this multi-vitamin and fluoride combination, making it impossible to identify a repurposing opportunity or assess supporting evidence. The combination is not registered in the US market and has no retrievable safety profile in this Evidence Pack.

**To proceed, the following is needed:**

- Resolve the drug identity issue: the combination entry lacks a DrugBank ID. Each constituent (e.g., Vitamin A → DB00162, Cyanocobalamin → DB00115) should be mapped individually and the TxGNN pipeline re-run per component or as a reformulated query.
- Obtain the original product label (package insert) to establish the intended indication and dosing context.
- Clarify the clinical question: if the intent is to evaluate a specific component (e.g., Folic Acid for neural tube defect prevention beyond its supplement label, or Vitamin D for immune-modulation), a targeted single-drug Evidence Pack should be generated.
- Once individual components are mapped, consolidate DDI data from DrugBank for the composite formulation, paying particular attention to Sodium Fluoride interactions and fat-soluble vitamin toxicity thresholds (Vitamins A and D).
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

